Evaluating Nanoparticles in Preclinical Research Using Microfluidic Systems
Оценка наночастиц в доклинических исследованиях с использованием микрофлюидных систем
2019-06-21
SCID: 54.1/mk28shsn
Discuss with AI
haemocompatibilitymicrofluidic systemsnanoparticle evaluationnanoparticle transport and uptakepreclinical research
Figures from the paper
Abstract (AI)
Nanoparticles (NPs) have found a wide range of applications in clinical therapeutic and diagnostic fields. However, currently most NPs are still in the preclinical evaluation phase with few approved for clinical use. Microfluidic systems can simulate dynamic fluid flows, chemical gradients, partitioning of multi-organs as well as local microenvironment controls, offering an efficient and cost-effective opportunity to fast screen NPs in physiologically relevant conditions. Here, in this review, we are focusing on summarizing key microfluidic platforms promising to mimic in vivo situations and test the performance of fabricated nanoparticles. Firstly, we summarize the key evaluation parameters of NPs which can affect their delivery efficacy, followed by highlighting the importance of microfluidic-based NP evaluation. Next, we will summarize main microfluidic systems effective in evaluating NP haemocompatibility, transport, uptake and toxicity, targeted accumulation and general efficacy respectively, and discuss the future directions for NP evaluation in microfluidic systems. The combination of nanoparticles and microfluidic technologies could greatly facilitate the development of drug delivery strategies and provide novel treatments and diagnostic techniques for clinically challenging diseases.
Key Findings
1
Integrating nanoparticles with microfluidic technologies could accelerate drug-delivery development and enable new treatments and diagnostic strategies for clinically challenging diseases.
2
Microfluidic platforms offer an efficient and cost-effective approach to evaluate nanoparticle haemocompatibility, transport, cellular uptake, toxicity, targeted accumulation, and overall efficacy.
3
Microfluidic systems can reproduce dynamic fluid flow, chemical gradients, multicompartment organ organization, and local microenvironments for physiologically relevant nanoparticle screening.
4
Most nanoparticles remain in preclinical evaluation, with relatively few receiving clinical approval despite broad therapeutic and diagnostic applications.
5
Nanoparticle evaluation should consider physicochemical and biological parameters that influence delivery efficacy, which microfluidic systems can assess under controlled conditions.
Research Object
Nanoparticles evaluated in physiologically relevant microfluidic systems
Research Subject
Nanoparticle haemocompatibility, transport, uptake, toxicity, targeted accumulation, and overall delivery efficacy
Publication Details
Publication Date
2019-06-21
Journal
Publisher
ISSN
Cited by
41
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest